DEALS: Millipore to buy Serologics for $1.4B

DEALS

WHO

WITH

WHAT

SCOOP

Millipore

Serologicals

$1.4B buyout

Serologicals commercializes technologies for manufacturing biologics and Millipore is a biosciences products company.

Bruker BioSciences

Bruker Optics

$135 buyout

Bruker Biosciences will buy Bruker Optics for $135 million in cash and stock. Both companies are majority-owned by five members of the Laukien family.

Fisher Scientific International

Clintrak Pharmaceutical Services

$125M buyout

Clintrak provides clinical trial printing services.

YM Biosciences

Eximias Pharmaceutical

$25M buyout

YM BioSciences is acquiring Eximias Pharmaceutical in a part-cash, part-stock deal. The full value of the acquisition was not disclosed.

Alteon

HaptoGuard

$8.8M buyout

The companies both have products for cardiovascular diseases, diabetes and other inflammatory diseases.

SRI International

Quality Clinical Labs

Buyout

QCL specializes in clinical hematology and chemistry evaluations and has about 50 biotech clients in the San Francisco Bay area.

Pfizer

Schwarz Pharma

$210M licensing deal

Schwarz has license its drug for overactive bladder to Pfizer. The company will gain a $100 million up-front payment and up to $110 million more in milestones.

Chemokine Therapeutics

Pharmaceutical Product Development

$2.5M licensing deal

Chemokine is reacquiring the licensing rights to CTCE-0214, which it granted to PPD in April 2003.

GSK

Japan Tobacco

Licensing deal

The deal is for the worldwide rights to a preclinical compound developed by Japan Tobacco.

ImQuest Pharmaceuticals

Samjin Pharmaceutical

Licensing deal

ImQuest has licensed the Piperazine Series of anti-cancer therapeutic compounds from Samjin.

ImQuest Pharmaceuticals

Isis Pharmaceuticals

Licensing deal

Isis has licensed its topical HIV therapy, Isis 5320, to ImQuest.

Athenagen

Osprey

Assets acquisition

Athenagen gains Osprey's lead drug candidate for Alzheimer's. Athenagen also nets a large library of analogs in the deal.

Lectus Therapeutics

NeuroServe

Asset acquisition

NeuroServe is an electrophysiology company which tests compounds on ion channels for pharmaceutical and biotech clients.

Future Systems

Rexahn

$35M sale

Rexahn agreed to sell regional sales rights to three of its experimental drugs to Korea's Future systems for $35.8 million while agreeing to buy $35 million in the company's stock.

Amgen

Alcon Collaboration

Collaboration

The companies will research, develop and commercialize therapeutics to treat eye diseases. Terms of the deal were not disclosed.

MedImmune

Elusys Therapeutics

Collaboration

The companies will collaborate to develop new therapies for infectious diseases. Details of the deal were not released.

Asuragen

Digene

Marketing deal

The companies have struck deal for the worldwide marketing and distribution of Asuragen's cystic fibrosis screening products.

Gilead

Corus

$25M investment

Gilead will become second-largest investor in Corus, a private biotech company that's been developing candidates for respiratory and infectious diseases.